These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35266826)

  • 1. Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones.
    Basarab GS; Ghorpade S; Gibhard L; Mueller R; Njoroge M; Peton N; Govender P; Massoudi LM; Robertson GT; Lenaerts AJ; Boshoff HI; Joerss D; Parish T; Durand-Reville TF; Perros M; Singh V; Chibale K
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0219221. PubMed ID: 35266826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Series of Spiropyrimidinetriones that Enhances DNA Cleavage Mediated by
    Byl JAW; Mueller R; Bax B; Basarab GS; Chibale K; Osheroff N
    ACS Infect Dis; 2023 Mar; 9(3):706-715. PubMed ID: 36802491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance.
    Collins JA; Osheroff N
    ACS Infect Dis; 2024 Apr; 10(4):1097-1115. PubMed ID: 38564341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between Zoliflodacin and
    Collins JA; Basarab GS; Chibale K; Osheroff N
    ACS Infect Dis; 2024 Aug; 10(8):3071-3082. PubMed ID: 39082980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
    Hameed P S; Patil V; Solapure S; Sharma U; Madhavapeddi P; Raichurkar A; Chinnapattu M; Manjrekar P; Shanbhag G; Puttur J; Shinde V; Menasinakai S; Rudrapatana S; Achar V; Awasthy D; Nandishaiah R; Humnabadkar V; Ghosh A; Narayan C; Ramya VK; Kaur P; Sharma S; Werngren J; Hoffner S; Panduga V; Kumar CN; Reddy J; Kumar K N M; Ganguly S; Bharath S; Bheemarao U; Mukherjee K; Arora U; Gaonkar S; Coulson M; Waterson D; Sambandamurthy VK; de Sousa SM
    J Med Chem; 2014 Jun; 57(11):4889-905. PubMed ID: 24809953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
    Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
    J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
    Govender P; Müller R; Singh K; Reddy V; Eyermann CJ; Fienberg S; Ghorpade SR; Koekemoer L; Myrick A; Schnappinger D; Engelhart C; Meshanni J; Byl JAW; Osheroff N; Singh V; Chibale K; Basarab GS
    J Med Chem; 2022 May; 65(9):6903-6925. PubMed ID: 35500229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update.
    Das S; Garg T; Srinivas N; Dasgupta A; Chopra S
    Curr Top Med Chem; 2019; 19(8):579-593. PubMed ID: 30834837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons.
    Gibson EG; Blower TR; Cacho M; Bax B; Berger JM; Osheroff N
    ACS Infect Dis; 2018 Aug; 4(8):1211-1222. PubMed ID: 29746087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis.
    Pandey B; Grover S; Tyagi C; Goyal S; Jamal S; Singh A; Kaur J; Grover A
    J Biomol Struct Dyn; 2018 Feb; 36(2):362-375. PubMed ID: 28071975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.
    Mdluli K; Ma Z
    Infect Disord Drug Targets; 2007 Jun; 7(2):159-68. PubMed ID: 17970226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.
    Pantel A; Petrella S; Matrat S; Brossier F; Bastian S; Reitter D; Jarlier V; Mayer C; Aubry A
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4524-9. PubMed ID: 21768507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.
    Aldred KJ; Blower TR; Kerns RJ; Berger JM; Osheroff N
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E839-46. PubMed ID: 26792518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis.
    Ouchi Y; Mukai T; Koide K; Yamaguchi T; Park JH; Kim H; Yokoyama K; Tamaru A; Gordon SV; Nakajima C; Suzuki Y
    Tuberculosis (Edinb); 2020 Jan; 120():101891. PubMed ID: 31778929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Potent DNA Gyrase Inhibitors Active against
    Pakamwong B; Thongdee P; Kamsri B; Phusi N; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Ariyachaokun K; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2022 Apr; 62(7):1680-1690. PubMed ID: 35347987
    [No Abstract]   [Full Text] [Related]  

  • 16. The pentapeptide repeat proteins MfpAMt and QnrB4 exhibit opposite effects on DNA gyrase catalytic reactions and on the ternary gyrase-DNA-quinolone complex.
    Mérens A; Matrat S; Aubry A; Lascols C; Jarlier V; Soussy CJ; Cavallo JD; Cambau E
    J Bacteriol; 2009 Mar; 191(5):1587-94. PubMed ID: 19060136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
    Chandran M; Renuka J; Sridevi JP; Pedgaonkar GS; Asmitha V; Yogeeswari P; Sriram D
    Int J Mycobacteriol; 2015 Jun; 4(2):104-15. PubMed ID: 26972878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioisosteric Design Identifies Inhibitors of
    Kamsri B; Pakamwong B; Thongdee P; Phusi N; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Sangswan J; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Leanpolchareanchai J; Goudar KE; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2023 May; 63(9):2707-2718. PubMed ID: 37074047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for Inhibition of Topoisomerase 1A by Gold(III) Macrocycles and Chelates Targeting Mycobacterium tuberculosis and Mycobacterium abscessus.
    Gupta R; Rodrigues Felix C; Akerman MP; Akerman KJ; Slabber CA; Wang W; Adams J; Shaw LN; Tse-Dinh YC; Munro OQ; Rohde KH
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483110
    [No Abstract]   [Full Text] [Related]  

  • 20. A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus.
    Ganapathy US; Del Río RG; Cacho-Izquierdo M; Ortega F; Lelièvre J; Barros-Aguirre D; Aragaw WW; Zimmerman MD; Lindman M; Dartois V; Gengenbacher M; Dick T
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0151421. PubMed ID: 34606340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.